Collaborate with usWhat’s new?
Insights

Defining the future of Clinical Care.

Our industry-leading approach is paving the way for personalized, patient-centric treatments.

Insight

10 Ways to Optimize and Accelerate Brand Performance using Prescription DTx

Overview

This whitepaper authored by Austin Speier and Syneos Health, details the 10 different ways pharma can optimize their portfolio and accelerate their brand performance using prescription DTx. 

An article by:

Austin Speier

Chief Strategy Officer

Related subjects:

Prescription Digital TherapeuticsPharma

Materials:

10 Ways to Optimize and Accelerate Brand Performance using Prescription DTx

Latest Insights

View all

02.12.2025

Prescription Digital Therapeutics
Podcast

Opportunities Abound for PDTs, with Click Therapeutics, Syneos Health Podcast

Shaheen Lakhan, MD, PhD, FAAN

By Shaheen Lakhan, MD, PhD, FAAN

Chief Medical Officer

The Digitization of Pharma Pipelines is Here — in the form of Software-Enhanced Drugs

01.30.2025

Software-Enhanced Drugs
Click SE
PDURS

The Digitization of Pharma Pipelines is Here — in the form of Software-Enhanced Drugs

12.30.2024

Technology
Depression
Prescription Digital Therapeutics

The Same Processes that Make Smartphones a Risk for Young People Must Be Harnessed to Provide Beneficial Digital Medical Treatments For All

Shaheen Lakhan, MD, PhD, FAAN

By Shaheen Lakhan, MD, PhD, FAAN

Chief Medical Officer

Medicine just got a digital upgrade: Software-Enhanced Drugs™

11.21.2024

Software-Enhanced Drugs
Click SE
PDURS

Medicine just got a digital upgrade: Software-Enhanced Drugs™

David Benshoof Klein

By David Benshoof Klein

Founder & CEO

Drugs Are Becoming ‘Smarter.’ Here’s How

11.11.2024

Software-Enhanced Drugs
Click SE

Drugs Are Becoming ‘Smarter.’ Here’s How

David Benshoof Klein

By David Benshoof Klein

Founder & CEO

10.24.2024

Software-Enhanced Drugs
Click SE
PDURS
Podcast

Could PDURS Be the Game Changer to Unlock Digital Therapeutics?

Randall Stanicky

By Randall Stanicky

Chief Financial Officer

10.23.2024

Prescription Digital Therapeutics
Podcast
Psychiatry

Software as Medicine: Prescription Digital Therapeutics with Dr. Shaheen Lakhan, Alluminate Podcast

Shaheen Lakhan, MD, PhD, FAAN

By Shaheen Lakhan, MD, PhD, FAAN

Chief Medical Officer

10.08.2024

Schizophrenia

A Personal Call for Mental Health Parity

Shaheen Lakhan, MD, PhD, FAAN

By Shaheen Lakhan, MD, PhD, FAAN

Chief Medical Officer

08.02.2024

Software-Enhanced Drugs
Click SE

The Future of Smart Drugs: FDA’s New Guidance on Digital Therapeutics Could Revolutionize Pharma and Patient Care

Randall Stanicky

By Randall Stanicky

Chief Financial Officer

08.01.2024

FDA
Software-Enhanced Drugs
Click SE
PDURS

The FDA’s PDURS Guidance: What Manufacturers Need to Know

Austin Speier

By Austin Speier

Chief Strategy Officer

02.12.2025

Prescription Digital Therapeutics
Podcast

Opportunities Abound for PDTs, with Click Therapeutics, Syneos Health Podcast

Shaheen Lakhan, MD, PhD, FAAN

By Shaheen Lakhan, MD, PhD, FAAN

Chief Medical Officer

The Digitization of Pharma Pipelines is Here — in the form of Software-Enhanced Drugs

01.30.2025

Software-Enhanced Drugs
Click SE
PDURS

The Digitization of Pharma Pipelines is Here — in the form of Software-Enhanced Drugs

12.30.2024

Technology
Depression
Prescription Digital Therapeutics

The Same Processes that Make Smartphones a Risk for Young People Must Be Harnessed to Provide Beneficial Digital Medical Treatments For All

Shaheen Lakhan, MD, PhD, FAAN

By Shaheen Lakhan, MD, PhD, FAAN

Chief Medical Officer

Medicine just got a digital upgrade: Software-Enhanced Drugs™

11.21.2024

Software-Enhanced Drugs
Click SE
PDURS

Medicine just got a digital upgrade: Software-Enhanced Drugs™

David Benshoof Klein

By David Benshoof Klein

Founder & CEO

Drugs Are Becoming ‘Smarter.’ Here’s How

11.11.2024

Software-Enhanced Drugs
Click SE

Drugs Are Becoming ‘Smarter.’ Here’s How

David Benshoof Klein

By David Benshoof Klein

Founder & CEO

10.24.2024

Software-Enhanced Drugs
Click SE
PDURS
Podcast

Could PDURS Be the Game Changer to Unlock Digital Therapeutics?

Randall Stanicky

By Randall Stanicky

Chief Financial Officer

10.23.2024

Prescription Digital Therapeutics
Podcast
Psychiatry

Software as Medicine: Prescription Digital Therapeutics with Dr. Shaheen Lakhan, Alluminate Podcast

Shaheen Lakhan, MD, PhD, FAAN

By Shaheen Lakhan, MD, PhD, FAAN

Chief Medical Officer

10.08.2024

Schizophrenia

A Personal Call for Mental Health Parity

Shaheen Lakhan, MD, PhD, FAAN

By Shaheen Lakhan, MD, PhD, FAAN

Chief Medical Officer

08.02.2024

Software-Enhanced Drugs
Click SE

The Future of Smart Drugs: FDA’s New Guidance on Digital Therapeutics Could Revolutionize Pharma and Patient Care

Randall Stanicky

By Randall Stanicky

Chief Financial Officer

08.01.2024

FDA
Software-Enhanced Drugs
Click SE
PDURS

The FDA’s PDURS Guidance: What Manufacturers Need to Know

Austin Speier

By Austin Speier

Chief Strategy Officer

View all

Discover our products

CT-152

CT-152

Rejoyn

Indication

Major Depressive Disorder (MDD)

Collaborator

Otsuka Pharmaceutical

Phase

Launch
AspyreRx

AspyreRx

AspyreRx™

Indication

Type 2 Diabetes

Collaborator

Phase

FDA Cleared
CT-132

CT-132

Indication

Episodic Migraine

Collaborator

Phase

Regulatory Review
CT-155

CT-155

Indication

Schizophrenia

Collaborator

Boehringer Ingelheim

Phase

Phase 3: Pivotal
CT-156

CT-156

Indication

Schizophrenia

Collaborator

Boehringer Ingelheim

Phase

Phase 2: Dev/Pilot
CT-102

CT-102

Indication

Opioid Use Disorder (OUD)

Collaborator

Phase

Phase 2: Dev/Pilot
CT-133

CT-133

Indication

Multiple Sclerosis (MS)

Collaborator

Phase

Phase 1: Discovery
CT-171

CT-171

Indication

Atopic Dermatitis

Collaborator

Phase

Phase 1: Discovery
CT-181

CT-181

Indication

Obesity

Collaborator

Phase

Phase 1: Discovery
CT-191

CT-191

Indication

Oncology

Collaborator

Phase

Phase 1: Discovery
CT-141

CT-141

Clickadian™

Indication

Insomnia

Collaborator

Phase

Phase 1: Discovery
CT-111

CT-111

Clickheart™

Indication

Acute Coronary Syndrome

Collaborator

Phase

Phase 1: Discovery
CT-152

CT-152

Rejoyn

Indication

Major Depressive Disorder (MDD)

Collaborator

Otsuka Pharmaceutical

Phase

Launch
AspyreRx

AspyreRx

AspyreRx™

Indication

Type 2 Diabetes

Collaborator

Phase

FDA Cleared
CT-132

CT-132

Indication

Episodic Migraine

Collaborator

Phase

Regulatory Review
CT-155

CT-155

Indication

Schizophrenia

Collaborator

Boehringer Ingelheim

Phase

Phase 3: Pivotal
CT-156

CT-156

Indication

Schizophrenia

Collaborator

Boehringer Ingelheim

Phase

Phase 2: Dev/Pilot
CT-102

CT-102

Indication

Opioid Use Disorder (OUD)

Collaborator

Phase

Phase 2: Dev/Pilot
CT-133

CT-133

Indication

Multiple Sclerosis (MS)

Collaborator

Phase

Phase 1: Discovery
CT-171

CT-171

Indication

Atopic Dermatitis

Collaborator

Phase

Phase 1: Discovery
CT-181

CT-181

Indication

Obesity

Collaborator

Phase

Phase 1: Discovery
CT-191

CT-191

Indication

Oncology

Collaborator

Phase

Phase 1: Discovery
CT-141

CT-141

Clickadian™

Indication

Insomnia

Collaborator

Phase

Phase 1: Discovery
CT-111

CT-111

Clickheart™

Indication

Acute Coronary Syndrome

Collaborator

Phase

Phase 1: Discovery

Stay up to date with news and updates